Alirocumab reduced the risk of recurrent ischemic cardiovascular events compared to placebo in patients on high-intensity statin therapy post-acute coronary syndrome.
Does alirocumab reduce recurrent ischemic cardiovascular events in patients with previous acute coronary syndrome receiving high-intensity statin therapy?
Alirocumab reduces the risk of recurrent ischemic cardiovascular events in patients with a history of acute coronary syndrome on background high-intensity statin therapy.
Absolute Event Rate: 0% vs 0%
Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).
Long-term legacy effects and cost-effectiveness still discussed in context of 2026 aggressive lipid lowering trials and new guidelines.
Schwartz et al. (Wed,) reported a other. Alirocumab reduced the risk of recurrent ischemic cardiovascular events compared to placebo in patients on high-intensity statin therapy post-acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: